CD55 Is Essential for CD103 Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity.

Recent studies traced inflammatory bowel disease in some patients to deficiency of CD55 [decay-accelerating factor (DAF)], but the mechanism underlying the linkage remained unclear. Herein, we studied the importance of DAF in enabling processes that program tolerance in the gut and the eye, two immune-privileged sites where immunosuppressive responses are continuously elicited. Unlike oral feeding or ocular injection of ovalbumin in wild-type (WT) mice, which induced dominant immune tolerance, identical treatment of DAF mice or DAF to WT bone marrow chimeras did not. While 10% to 30% of mesenteric and submandibular lymph node CD4 cells became robust T-regulatory cells (Tregs) in WT forkhead box P3 (Foxp3)-green fluorescent protein mice, few in either site became Tregs with little suppressor activity in DAF Foxp3-green fluorescent protein mice. Phenotyping of CD103 dendritic cells (DCs) from the ovalbumin-fed DAF mice showed impaired expression of inducer of costimulation (ICOS) ligand, programmed death receptor 1-ligand 1 (PD1-L1), CxxxC chemokine receptor 1 (Cx3CR1), CCR7, and CCR9. Analyses of elicited DAF Foxp3 Tregs showed reduced expression of interferon regulatory factor 8 (IRF-8)/aldehyde dehydrogenase 1 family member A2 (Aldh1a2) and glycoprotein A repetitions predominant/latency-associated protein associated with Treg transforming growth factor-β production and presentation, as well as integrin β6/integrin β8 associated with Treg and CD103 DC transforming growth factor-β release. Thus, DAF is required for the properties of CD103 DCs and their naïve CD4 cell partners that together program tolerance.